Cargando…

Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment

The synthesis of a new nanogel drug carrier system loaded with the anti-cancer drug doxorubicin (DOX) is presented. Poly(2-oxazoline) (POx) based nanogels from block copolymer micelles were cross-linked and covalently loaded with DOX using pH-sensitive Schiff’ base chemistry. DOX loaded POx based na...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoelzer, Doerte, Leiske, Meike N., Hartlieb, Matthias, Bus, Tanja, Pretzel, David, Hoeppener, Stephanie, Kempe, Kristian, Thierbach, René, Schubert, Ulrich S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976466/
https://www.ncbi.nlm.nih.gov/pubmed/29854280
http://dx.doi.org/10.18632/oncotarget.24806
_version_ 1783327181396508672
author Hoelzer, Doerte
Leiske, Meike N.
Hartlieb, Matthias
Bus, Tanja
Pretzel, David
Hoeppener, Stephanie
Kempe, Kristian
Thierbach, René
Schubert, Ulrich S.
author_facet Hoelzer, Doerte
Leiske, Meike N.
Hartlieb, Matthias
Bus, Tanja
Pretzel, David
Hoeppener, Stephanie
Kempe, Kristian
Thierbach, René
Schubert, Ulrich S.
author_sort Hoelzer, Doerte
collection PubMed
description The synthesis of a new nanogel drug carrier system loaded with the anti-cancer drug doxorubicin (DOX) is presented. Poly(2-oxazoline) (POx) based nanogels from block copolymer micelles were cross-linked and covalently loaded with DOX using pH-sensitive Schiff’ base chemistry. DOX loaded POx based nanogels showed a toxicity profile comparable to the free drug, while unloaded drug carriers showed no toxicity. Hemolytic activity and erythrocyte aggregation of the drug delivery system was found to be low and cellular uptake was investigated by flow cytometry and fluorescence microscopy. While the amount of internalized drug was enhanced when incorporated into a nanogel, the release of the drug into the nucleus was delayed. For in vivo investigations the nanogel drug delivery system was combined with a metronomic treatment of DOX. Low doses of free DOX were compared to equivalent DOX loaded nanogels in a xenograft mouse model. Treatment with POx based nanogels revealed a significant tumor growth inhibition and increase in survival time, while pure DOX alone had no effect on tumor progression. The biodistribution was investigated by microscopy of organs of mice and revealed a predominant localization of DOX within tumorous tissue. Thus, the POx based nanogel system revealed a therapeutic efficiency despite the low DOX concentrations and could be a promising strategy to control tumor growth with fewer side effects.
format Online
Article
Text
id pubmed-5976466
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-59764662018-05-31 Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment Hoelzer, Doerte Leiske, Meike N. Hartlieb, Matthias Bus, Tanja Pretzel, David Hoeppener, Stephanie Kempe, Kristian Thierbach, René Schubert, Ulrich S. Oncotarget Research Paper The synthesis of a new nanogel drug carrier system loaded with the anti-cancer drug doxorubicin (DOX) is presented. Poly(2-oxazoline) (POx) based nanogels from block copolymer micelles were cross-linked and covalently loaded with DOX using pH-sensitive Schiff’ base chemistry. DOX loaded POx based nanogels showed a toxicity profile comparable to the free drug, while unloaded drug carriers showed no toxicity. Hemolytic activity and erythrocyte aggregation of the drug delivery system was found to be low and cellular uptake was investigated by flow cytometry and fluorescence microscopy. While the amount of internalized drug was enhanced when incorporated into a nanogel, the release of the drug into the nucleus was delayed. For in vivo investigations the nanogel drug delivery system was combined with a metronomic treatment of DOX. Low doses of free DOX were compared to equivalent DOX loaded nanogels in a xenograft mouse model. Treatment with POx based nanogels revealed a significant tumor growth inhibition and increase in survival time, while pure DOX alone had no effect on tumor progression. The biodistribution was investigated by microscopy of organs of mice and revealed a predominant localization of DOX within tumorous tissue. Thus, the POx based nanogel system revealed a therapeutic efficiency despite the low DOX concentrations and could be a promising strategy to control tumor growth with fewer side effects. Impact Journals LLC 2018-04-27 /pmc/articles/PMC5976466/ /pubmed/29854280 http://dx.doi.org/10.18632/oncotarget.24806 Text en Copyright: © 2018 Hoelzer et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Hoelzer, Doerte
Leiske, Meike N.
Hartlieb, Matthias
Bus, Tanja
Pretzel, David
Hoeppener, Stephanie
Kempe, Kristian
Thierbach, René
Schubert, Ulrich S.
Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment
title Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment
title_full Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment
title_fullStr Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment
title_full_unstemmed Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment
title_short Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment
title_sort tumor targeting with ph-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976466/
https://www.ncbi.nlm.nih.gov/pubmed/29854280
http://dx.doi.org/10.18632/oncotarget.24806
work_keys_str_mv AT hoelzerdoerte tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment
AT leiskemeiken tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment
AT hartliebmatthias tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment
AT bustanja tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment
AT pretzeldavid tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment
AT hoeppenerstephanie tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment
AT kempekristian tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment
AT thierbachrene tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment
AT schubertulrichs tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment